


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 37991-0018

Applicant: Georges RAWADI et al. Confirmation No. 6623
Appl. No.: 10/665,816 Examiner: Unassigned
Filing Date: September 19, 2003 Art Unit: 1646
Title: GSK-3BETA INHIBITORS IN THE TREATMENT OF BONE-RELATED DISEASES



**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE STATEMENT

The relevance of the documents are described in the present specification.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: February 12, 2004

By Patricia D. Granados

Customer No. 26633
HELLER EHRMAN WHITE &
MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, DC 20006
Telephone: (202) 912-2142
Facsimile: (202) 912-2020

Patricia D. Granados
Attorney for Applicant
Registration No. 33,683

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/665,816
Filing Date	September 19, 2003
First Named Inventor	Georges RAWADI et al.
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	37991-0018

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A01	ADNAN ALI et al., "Glycogen Synthase Kinase-3: Properties, Functions, and Regulation", Chem. Rev. 2001, pp. 2527-2540, Vol. 101	
	A02	ROLAND BARON, D.D.S., Ph.D., "Anatomy and Ultrastructure of Bone", Primer on the metabolic bone diseases and disorders of mineral metabolism, 4th edition, Raven Press, NY	
	A03	BRADLEY W. DOBLE et al., "GSK-3: tricks of the trade for a multi-tasking kinase", Journal of Cell Science, 2003, pp. 1175-1186, Vol. 116	
	A04	SHEELAGH FRAME et al., "GSK3 takes center stage more than 20 years after its discovery", Biochem. J., 2001, pp. 1-16, Vol. 359	
	A05	JOERG HUELSKEN et al., "The Wnt signaling pathway", Cell Science at a Glance, Journal of Cell Science, 2002, pp. 3977-3978, Vol. 115	
	A06	MASAKI KATO et al., "Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor", the Journal of Cell Biology, April 15, 2002, pp. 303-314, Vol. 157, No. 2	
	A07	JEFFREY R. MILLER, "The Wnts", Genome Biol., 2001, REVIEWS3001, PP. 3001.1-3001.15, Vol 3, No. 1	
	A08	MASCHA VAN NOORT et al., "Wnt Signaling Controls the Phosphorylation Status of β -Catenin", The Journal of Biological Chemistry, 2002, pp. 17901-17905, Vol. 277, No. 20	
	A09	MIGUEL A. ORTEGA et al., "Pyrazolo[3,4-b]quinoxalines. A New Class of Cyclin-Dependent Kinases Inhibitors", Bioorganic & Medicinal Chemistry, 2002, pp. 2177-2184, Vol. 10	
	A10	T.K. SAMPATH et al., "Isolation of osteogenin, and extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography", Proc. Natl. Acad. Sci. USA, October 1987, pp. 7109-7113, Vol. 84	
	A11	A.F. TENCER et al., "The effect of local controlled release of sodium fluoride on the stimulation of bone growth", Journal of Biomedical Materials Research, 1989, pp. 571-589, Vol. 23	
	A12	MARC VAN DE WETERING et al., "Armadillo Coactivates Transcription Driven by the Product of the Drosophila Segment Polarity Gene dTCF", Cell, March 21, 1997, pp. 789-799, Vol. 88	
	A13	JASON WITHERINGTON et al., "5-Aryl-pyrazolo[3,4-b]pyridazines: Potent Inhibitors of Glycogen Synthase Kinase-3 (GSK-3)", Bioorganic & Medicinal Chemistry Letters, 2003, pp. 1581-1584, Vol. 13	
	A14	JAMES ROBERT WOODGETT, "Molecular cloning and expression of glycogen synthase kinase-3/Factor A", The EMBO Journal, 1990, pp. 2431-2438, Vol. 9, No. 8	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

